These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

918 related articles for article (PubMed ID: 19372479)

  • 1. SPECT/CT with 99mTc-MAA in radioembolization with 90Y microspheres in patients with hepatocellular cancer.
    Hamami ME; Poeppel TD; Müller S; Heusner T; Bockisch A; Hilgard P; Antoch G
    J Nucl Med; 2009 May; 50(5):688-92. PubMed ID: 19372479
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The significance of 99mTc-MAA SPECT/CT liver perfusion imaging in treatment planning for 90Y-microsphere selective internal radiation treatment.
    Ahmadzadehfar H; Sabet A; Biermann K; Muckle M; Brockmann H; Kuhl C; Wilhelm K; Biersack HJ; Ezziddin S
    J Nucl Med; 2010 Aug; 51(8):1206-12. PubMed ID: 20660379
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intraarterial Hepatic SPECT/CT Imaging Using 99mTc-Macroaggregated Albumin in Preparation for Radioembolization.
    Gates VL; Singh N; Lewandowski RJ; Spies S; Salem R
    J Nucl Med; 2015 Aug; 56(8):1157-62. PubMed ID: 26089551
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Angiography-based C-arm CT for the assessment of extrahepatic shunting before radioembolization.
    Heusner TA; Hamami ME; Ertle J; Hahn S; Poeppel T; Hilgard P; Bockisch A; Forsting M; Antoch G
    Rofo; 2010 Jul; 182(7):603-8. PubMed ID: 20183775
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A simple method for estimating dose delivered to hepatocellular carcinoma after yttrium-90 glass-based radioembolization therapy: preliminary results of a proof of concept study.
    Kokabi N; Galt JR; Xing M; Camacho JC; Barron BJ; Schuster DM; Kim HS
    J Vasc Interv Radiol; 2014 Feb; 25(2):277-87. PubMed ID: 24461133
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Predictive Value of 99mTc-MAA SPECT for 90Y-Labeled Resin Microsphere Distribution in Radioembolization of Primary and Secondary Hepatic Tumors.
    Ilhan H; Goritschan A; Paprottka P; Jakobs TF; Fendler WP; Todica A; Bartenstein P; Hacker M; Haug AR
    J Nucl Med; 2015 Nov; 56(11):1654-60. PubMed ID: 26315830
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Systematic evaluation of tumoral 99mTc-MAA uptake using SPECT and SPECT/CT in 502 patients before 90Y radioembolization.
    Ilhan H; Goritschan A; Paprottka P; Jakobs TF; Fendler WP; Bartenstein P; Hacker M; Haug AR
    J Nucl Med; 2015 Mar; 56(3):333-8. PubMed ID: 25655623
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Computed tomography hepatic arteriography has a hepatic falciform artery detection rate that is much higher than that of digital subtraction angiography and 99mTc-MAA SPECT/CT: implications for planning 90Y radioembolization?
    Burgmans MC; Too CW; Kao YH; Goh AS; Chow PK; Tan BS; Tay KH; Lo RH
    Eur J Radiol; 2012 Dec; 81(12):3979-84. PubMed ID: 22954411
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dosimetry based on 99mTc-macroaggregated albumin SPECT/CT accurately predicts tumor response and survival in hepatocellular carcinoma patients treated with 90Y-loaded glass microspheres: preliminary results.
    Garin E; Lenoir L; Rolland Y; Edeline J; Mesbah H; Laffont S; Porée P; Clément B; Raoul JL; Boucher E
    J Nucl Med; 2012 Feb; 53(2):255-63. PubMed ID: 22302962
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Partition Model-Based 99mTc-MAA SPECT/CT Predictive Dosimetry Compared with 90Y TOF PET/CT Posttreatment Dosimetry in Radioembolization of Hepatocellular Carcinoma: A Quantitative Agreement Comparison.
    Gnesin S; Canetti L; Adib S; Cherbuin N; Silva Monteiro M; Bize P; Denys A; Prior JO; Baechler S; Boubaker A
    J Nucl Med; 2016 Nov; 57(11):1672-1678. PubMed ID: 27307346
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Correlation of Technetium-99m Macroaggregated Albumin and Yttrium-90 Glass Microsphere Biodistribution in Hepatocellular Carcinoma: A Retrospective Review of Pretreatment Single Photon Emission CT and Posttreatment Positron Emission Tomography/CT.
    Haste P; Tann M; Persohn S; LaRoche T; Aaron V; Mauxion T; Chauhan N; Dreher MR; Johnson MS
    J Vasc Interv Radiol; 2017 May; 28(5):722-730.e1. PubMed ID: 28238581
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Measurement of the Tumor-to-Normal Ratio for Radioembolization of Hepatocellular Carcinoma: A Prospective Study Comparing 2-Dimensional Perfusion Angiography, Technetium-99m Macroaggregated Albumin, and Yttrium-90 SPECT/CT.
    Brunson CP; McGregor HJ; Hennemeyer CT; Patel MV; Woodhead GJ; Young SJ
    J Vasc Interv Radiol; 2024 Jan; 35(1):94-101. PubMed ID: 37783268
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of absorbed doses to the tumoral and non-tumoral liver in HCC patients undergoing
    Noipinit N; Sukprakun C; Siricharoen P; Khamwan K
    Ann Nucl Med; 2024 Mar; 38(3):210-218. PubMed ID: 38142421
    [TBL] [Abstract][Full Text] [Related]  

  • 14. 99mTc-macroaggregated albumin poorly predicts the intrahepatic distribution of 90Y resin microspheres in hepatic radioembolization.
    Wondergem M; Smits ML; Elschot M; de Jong HW; Verkooijen HM; van den Bosch MA; Nijsen JF; Lam MG
    J Nucl Med; 2013 Aug; 54(8):1294-301. PubMed ID: 23749996
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of perfused volume segmentation between cone-beam CT and
    Martin M; Hocquelet A; Debordeaux F; Bordenave L; Blanc JF; Papadopoulos P; Lapuyade B; Trillaud H; Pinaquy JB
    Diagn Interv Imaging; 2021 Jan; 102(1):45-52. PubMed ID: 33032960
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Radioembolization with infusion of yttrium-90 microspheres into a right inferior phrenic artery with hepatic tumor supply is feasible and safe.
    Burgmans MC; Kao YH; Irani FG; Dames EL; Teo TK; Goh AS; Chow PK; Tay KH; Lo RH
    J Vasc Interv Radiol; 2012 Oct; 23(10):1294-301. PubMed ID: 22922039
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical and Dosimetric Implications of Calculating Lung Shunt Fraction for Hepatic
    Struycken L; Patel M; Kuo P; Hennemeyer C; Woodhead G; McGregor H
    AJR Am J Roentgenol; 2022 Apr; 218(4):728-737. PubMed ID: 34704460
    [No Abstract]   [Full Text] [Related]  

  • 18. Evaluation of factors affecting tumor response and survival in patients with primary and metastatic liver cancer treated with microspheres.
    Demirelli S; Erkilic M; Oner AO; Budak ES; Gunduz S; Ozgur O; Bozcuk H; Sindel HT; Boz A
    Nucl Med Commun; 2015 Apr; 36(4):340-9. PubMed ID: 25563137
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety of a Scout Dose Preceding Hepatic Radioembolization with 166Ho Microspheres.
    Prince JF; van Rooij R; Bol GH; de Jong HW; van den Bosch MA; Lam MG
    J Nucl Med; 2015 Jun; 56(6):817-23. PubMed ID: 25931477
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical impact of (99m)Tc-MAA SPECT/CT-based dosimetry in the radioembolization of liver malignancies with (90)Y-loaded microspheres.
    Garin E; Rolland Y; Laffont S; Edeline J
    Eur J Nucl Med Mol Imaging; 2016 Mar; 43(3):559-75. PubMed ID: 26338177
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 46.